Spots Global Cancer Trial Database for Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
Official Title: Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma
Study ID: NCT00316420
Conditions
Study Description
Brief Summary: The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Swedish Medical Center Cancer Institute, Seattle, Washington, United States
Contact Details
Name: Philip Gold, MD
Affiliation: Swedish Medical Center Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Henry Kaplan, MD
Affiliation: Swedish Medical Center Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
